Recurrent Squamous Cell Lung Carcinoma Withdrawn Phase 1 / 2 Trials for Docetaxel (DB01248)

IndicationStatusPhase
DBCOND0044226 (Recurrent Squamous Cell Lung Carcinoma)Withdrawn1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02536495Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung CancerTreatment